Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 70

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 1
Chunk 70
---
 and non-correlations within the data. In terms of actionable output, the analytical
results confirmed at least two demographic co-variates for the ongoing trial, and also provided a starting point for deeper physiological
and molecular studies.

Our
Supply Chain and Customer Base

We
have launched our businesses using funds from our initial public offering and through our partnerships and relationships. We have a strategic
relationship with FSHD Society, a leading non-governmental organization, for AI/ML analysis of clinical trial data for patients with
a rare neuromuscular disorder. We also have several other developing strategic relationships in the project design phase. The Company
has executed a joint development deal for a biologics discovery phase opportunity that is directed toward targeted cancer therapeutics.
The Company has also obtained exclusive worldwide rights to a Phase II ready glioblastoma drug and a discovery phase hepatocellular carcinoma
drug from universities. Since we intend to conduct late-stage clinical trials with partners on rescued therapeutic assets, there will
be a requirement of drug product or other significant services to plan and execute our clinical development programs. The success of
our partnered clinical development programs will require adequate availability of raw materials and drug product for our R&D and
clinical trials, and, in some cases, may also require establishment of third-party arrangements to obtain finished drug product that
is manufactured appropriately under industry-standard guidelines, and packaged for clinical use or sale. Since we are a digital biopharmaceutical
company, our clinical development programs will also require, in some cases, the establishment of third-party relationships for execution
and completion of clinical trials.

Our
Market Opportunity

One
aim of our business is to “rescue” drugs that have failed in Phase III clinical trials by using our technology to analyze
all available data with the goal of designing a precision medicine clinical trial that will have a better chance of being successful.
The graphic below illustrates the estimated market opportunity for these failed drugs. The top arrow shows the number of failed Phase
III trials for several disease categories over a 5-year period. The arrows below provide our assumptions for narrowing or discounting
certain parameters associated with the market size calculation. The final arrow shows the math behind the $47.1 billion market opportunity.
To date, we have not penetrated the failed drug market, however; we are actively searching for failed drug opportunities.

 11 

Identification
of candidates with potential for rescue may be challenging and require significant resources, and once these assets are identified the
Company may find it